[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition-gad":3},{"id":4,"title":5,"abbr":6,"assessments":7,"bgClass":36,"body":37,"category":6,"comorbidities":44,"description":73,"dsmCriteria":74,"etiology":105,"extension":142,"heroSubtitle":143,"heroTitle":144,"icdCode":145,"icon":146,"iconClass":147,"labelClass":6,"lastReviewed":6,"meta":148,"name":171,"navigation":172,"onsetAge":173,"path":174,"prevalence":175,"ratio":176,"responseRate":177,"seo":178,"slug":179,"sources":180,"stem":200,"takeaways":6,"tools":6,"treatments":201,"__hash__":237},"conditions\u002Fconditions\u002Fgad.md","GAD Clinical Guide: GAD-7, DSM-5-TR and CBT Protocols",null,[8,15,22,29],{"name":9,"fullName":10,"description":11,"scoring":12,"timeframe":13,"icon":14},"GAD-7","Generalized Anxiety Disorder-7","Brief 7-item self-report measure of GAD symptom severity; most widely used screening tool in primary care.","0-4 minimal, 5-9 mild, 10-14 moderate, 15-21 severe anxiety; score ≥10 suggests GAD","2-3 minutes","ph:clipboard-text",{"name":16,"fullName":17,"description":18,"scoring":19,"timeframe":20,"icon":21},"PSWQ","Penn State Worry Questionnaire","Criterion-standard 16-item measure of trait worry, the cardinal feature of GAD.","Score range 16-80; cutoff ≥62 suggests clinically significant worry; highly sensitive to treatment change","5-7 minutes","ph:warning-circle",{"name":23,"fullName":24,"description":25,"scoring":26,"timeframe":27,"icon":28},"HAM-A","Hamilton Anxiety Rating Scale","Clinician-rated 14-item scale assessing psychological and somatic anxiety symptoms.","\u003C17 mild, 18-24 mild-moderate, 25-30 moderate-severe, >30 severe anxiety","15-20 minutes","ph:user-circle",{"name":30,"fullName":31,"description":32,"scoring":33,"timeframe":34,"icon":35},"BAI","Beck Anxiety Inventory","21-item self-report focusing on somatic symptoms of anxiety over the past week.","0-7 minimal, 8-15 mild, 16-25 moderate, 26-63 severe anxiety","5-10 minutes","ph:heart","bg-amber-500\u002F10",{"type":38,"value":39,"toc":40},"minimark",[],{"title":41,"searchDepth":42,"depth":42,"links":43},"",2,[],[45,50,55,60,65,69],{"condition":46,"prevalence":47,"note":48,"icon":49},"Major Depressive Disorder","40-60%","Often develops secondary to chronic worry and functional impairment from GAD","ph:cloud-rain",{"condition":51,"prevalence":52,"note":53,"icon":54},"Other Anxiety Disorders","30-50%","Panic disorder, social anxiety disorder, and specific phobias commonly co-occur","ph:warning-octagon",{"condition":56,"prevalence":57,"note":58,"icon":59},"Substance Use Disorders","15-30%","Alcohol and benzodiazepine misuse for self-medication; worsens anxiety long-term","ph:pill",{"condition":61,"prevalence":62,"note":63,"icon":64},"Somatic Symptom Disorder","20-30%","Excessive health anxiety and preoccupation with physical symptoms","ph:first-aid",{"condition":66,"prevalence":52,"note":67,"icon":68},"Irritable Bowel Syndrome","Bidirectional gut-brain axis; chronic worry exacerbates GI symptoms","ph:circle-wavy",{"condition":70,"prevalence":47,"note":71,"icon":72},"Insomnia Disorder","Difficulty falling asleep due to worry; sleep disturbance maintains anxiety","ph:moon","Clinical guide to Generalized Anxiety Disorder: assessment protocols (GAD-7, PSWQ, HAM-A), diagnostic criteria, comorbidities, and treatment with CBT.",[75,80,86,97],{"title":76,"subtitle":77,"icon":21,"items":78},"Criterion A: Excessive Worry","Persistent worry for at least 6 months",[79],"Excessive anxiety and worry occurring more days than not about a number of events or activities",{"title":81,"subtitle":82,"icon":83,"items":84},"Criterion B: Control","Difficulty controlling worry","ph:shield-warning",[85],"The individual finds it difficult to control the worry",{"title":87,"subtitle":88,"icon":89,"items":90},"Criterion C: Associated Symptoms","3+ required (only 1 in children):","ph:lightning",[91,92,93,94,95,96],"Restlessness or Feeling Keyed Up (Feeling on edge, unable to relax)","Easily Fatigued (Mental and physical exhaustion from worry)","Difficulty Concentrating (Mind going blank, distracted by worry)","Irritability (Increased impatience and frustration)","Muscle Tension (Chronic tightness, especially jaw, neck, shoulders)","Sleep Disturbance (Difficulty falling\u002Fstaying asleep, restless sleep)",{"title":98,"subtitle":99,"icon":100,"items":101},"Additional Requirements","Diagnostic caveats:","ph:warning",[102,103,104],"Causes clinically significant distress or functional impairment","Not attributable to substance use or medical condition","Not better explained by another mental disorder",[106,115,124,133],{"category":107,"factors":108,"icon":113,"color":114},"Neurobiological",[109,110,111,112],"Amygdala hyperactivity (threat detection)","Prefrontal cortex hypoactivity (worry regulation)","Anterior cingulate cortex dysfunction","GABA and serotonin dysregulation","ph:brain","primary",{"category":116,"factors":117,"icon":122,"color":123},"Genetic",[118,119,120,121],"Heritability: 30-40%","Polygenic risk involving multiple genes","SLC6A4 polymorphisms","COMT gene variants","ph:dna","secondary",{"category":125,"factors":126,"icon":131,"color":132},"Environmental",[127,128,129,130],"Childhood adversity and overprotective parenting","Chronic stress and major life transitions","Socioeconomic instability","Medical illness","ph:globe","accent",{"category":134,"factors":135,"icon":140,"color":141},"Psychological",[136,137,138,139],"Intolerance of uncertainty","Negative beliefs about worry","Thought-action fusion","Attentional bias toward threat","ph:lightbulb","info","md","An anxiety disorder characterized by excessive, persistent worry about multiple domains of life, accompanied by physical tension and difficulty controlling the worry.","Generalized \u003Cbr \u002F> \u003Cspan class='text-gradient-flow'>Anxiety Disorder\u003C\u002Fspan>","F41.1","ph:wind","text-amber-500",{"faqs":149},[150,153,156,159,162,165,168],{"question":151,"answer":152},"What is Generalized Anxiety Disorder?","Generalized Anxiety Disorder (GAD) is an anxiety disorder defined in DSM-5-TR (ICD-11 code F41.1) by excessive, persistent worry about multiple domains of life lasting at least 6 months, accompanied by physical tension and difficulty controlling the worry. The worry is hard to control and produces clinically significant distress or functional impairment. Three or more associated symptoms are required for adults: restlessness, fatigue, difficulty concentrating, irritability, muscle tension, or sleep disturbance.",{"question":154,"answer":155},"What are the symptoms of Generalized Anxiety Disorder?","Core symptoms include excessive worry about multiple life domains (work, health, family, finances), difficulty controlling the worry, and physical and cognitive symptoms that accompany the anxiety. Associated symptoms include restlessness or feeling on edge, easy fatigue, difficulty concentrating or mind going blank, irritability, muscle tension (especially jaw, neck, and shoulders), and sleep disturbance. Symptoms must be present more days than not for at least 6 months and cause functional impairment to meet diagnostic threshold.",{"question":157,"answer":158},"How is Generalized Anxiety Disorder diagnosed?","Diagnosis is made by a clinician using DSM-5-TR criteria, supported by validated scales. The GAD-7 (7 items, 2 to 3 minutes) is the most widely used screener; a score of 10 or above suggests probable GAD with 89% sensitivity and 82% specificity. The PSWQ (Penn State Worry Questionnaire) measures trait worry. The HAM-A is a clinician-rated alternative for severity. A full clinical evaluation rules out medical conditions (hyperthyroidism, cardiac issues), substance-induced anxiety, and other anxiety or mood disorders that might better explain the presentation.",{"question":160,"answer":161},"What causes Generalized Anxiety Disorder?","GAD has moderate genetic heritability of 30 to 40 percent, with polygenic risk involving multiple genes including SLC6A4 and COMT variants. Neurobiologically, GAD involves amygdala hyperactivity for threat detection, prefrontal cortex hypoactivity for worry regulation, anterior cingulate cortex dysfunction, and GABA and serotonin dysregulation. Environmental contributors include childhood adversity, overprotective parenting, chronic stress, major life transitions, and socioeconomic instability. Psychological maintaining factors include intolerance of uncertainty, negative beliefs about worry, and attentional bias toward threat.",{"question":163,"answer":164},"How is Generalized Anxiety Disorder treated?","First-line treatments are Cognitive Behavioral Therapy (CBT) and SSRIs or SNRIs. CBT for GAD targets worry content, intolerance of uncertainty, cognitive distortions, and avoidance behaviors over 12 to 16 sessions, producing 50 to 60 percent response rates with effect sizes around 0.8 to 1.0. SSRIs (escitalopram, sertraline) and SNRIs (duloxetine, venlafaxine) produce comparable response rates with 4 to 8 weeks for full effect. Acceptance and Commitment Therapy is an evidence-based alternative. Buspirone, pregabalin, and mindfulness-based stress reduction serve as adjuncts.",{"question":166,"answer":167},"How long does Generalized Anxiety Disorder last?","GAD is typically chronic, with symptoms waxing and waning over years or decades if untreated. Average age of onset is around 31, and lifetime prevalence is approximately 5 to 6 percent of the population. With treatment, 50 to 60 percent of patients achieve clinical response, and many achieve remission, but relapse is common after treatment ends. Continuing SSRI or SNRI medication for 12 or more months after remission reduces relapse risk. CBT produces durable effects post-treatment, and patients who learn the skills tend to maintain gains better than those treated with medication alone.",{"question":169,"answer":170},"Can Generalized Anxiety Disorder be cured?","GAD is generally managed rather than cured, though many patients achieve sustained remission with treatment. Approximately 50 to 60 percent of patients respond to first-line CBT or pharmacotherapy, and a meaningful subset achieve full remission. Relapse rates are higher when treatment is stopped early, particularly with medication alone; CBT skills tend to produce more durable effects because patients learn techniques they can deploy independently. Patients with comorbid depression, persistent worry beliefs, or significant childhood adversity may need longer treatment courses or augmentation strategies.","Generalized Anxiety Disorder",true,"~31","\u002Fconditions\u002Fgad","5-6%","2:1","50-60%",{"title":5,"description":73},"gad",[181,184,188,191,194,197],{"title":182,"citation":183,"icon":14},"GAD-7 Validation","Spitzer RL, Kroenke K, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.",{"title":185,"citation":186,"icon":187},"DSM-5-TR Criteria","American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.","ph:book-open",{"title":189,"citation":190,"icon":113},"CBT for GAD Meta-Analysis","Cuijpers P, Cristea IA, et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis. World Psychiatry. 2016;15(3):245-258.",{"title":192,"citation":193,"icon":59},"Pharmacotherapy Efficacy","Baldwin DS, Anderson IM, et al. Evidence-based pharmacological treatment of anxiety disorders. J Psychopharmacol. 2014;28(5):403-439.",{"title":195,"citation":196,"icon":21},"Intolerance of Uncertainty Model","Dugas MJ, Gagnon F, et al. Generalized anxiety disorder: a preliminary test of a conceptual model. Behav Res Ther. 1998;36(2):215-226.",{"title":198,"citation":199,"icon":113},"Neurobiology of GAD","Etkin A, Prater KE, et al. Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder. Arch Gen Psychiatry. 2009;66(12):1361-1372.","conditions\u002Fgad",[202,208,213,218,225,231],{"name":203,"type":204,"description":205,"efficacy":206,"notes":207,"icon":113},"Cognitive Behavioral Therapy (CBT)","First-line","Structured therapy targeting worry content, intolerance of uncertainty, cognitive distortions, and avoidance behaviors.","50-60% response rate; effect size 0.8-1.0; durable effects post-treatment","12-16 sessions; includes cognitive restructuring, worry exposure, relaxation training",{"name":209,"type":204,"description":210,"efficacy":211,"notes":212,"icon":59},"SSRIs\u002FSNRIs","Escitalopram, sertraline, duloxetine, venlafaxine approved for GAD. Increase serotonin\u002Fnorepinephrine.","50-60% response rate; 4-8 weeks for full effect; superior to placebo (NNT ~5)","Start low, titrate slowly; continue 12+ months after remission to prevent relapse",{"name":214,"type":204,"description":215,"efficacy":216,"notes":217,"icon":140},"Acceptance and Commitment Therapy (ACT)","Mindfulness-based therapy focusing on acceptance of worry rather than control; values-based action.","Comparable to CBT; particularly effective for chronic, treatment-resistant worry","Targets experiential avoidance and cognitive fusion with anxious thoughts",{"name":219,"type":220,"description":221,"efficacy":222,"notes":223,"icon":224},"Buspirone","Adjunct","5-HT1A partial agonist; anxiolytic without sedation or dependence risk.","Modest effect; 30-40% response rate; no immediate relief (2-4 weeks onset)","Useful for patients with substance use history; can augment SSRIs","ph:circle",{"name":226,"type":220,"description":227,"efficacy":228,"notes":229,"icon":230},"Pregabalin","Anticonvulsant with anxiolytic properties; modulates calcium channels.","Approved in Europe; 40-50% response rate; faster onset than SSRIs","Monitor for sedation and weight gain; abuse potential lower than benzodiazepines","ph:flask",{"name":232,"type":220,"description":233,"efficacy":234,"notes":235,"icon":236},"Mindfulness-Based Stress Reduction (MBSR)","8-week structured program teaching mindfulness meditation and body awareness.","Moderate effect sizes; reduces worry and physiological arousal","Can be combined with CBT or medication; requires practice commitment","ph:eye","w2wIOFHrp8voLcmDB_RXT7Qi1guUQmCD2HYtI-oFfCM"]